Ignite Creation Date:
2024-05-05 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00479739
Status:
COMPLETED
Last Update Posted:
2016-09-15
First Post:
2007-05-25
Brief Title:
CONCEPT A 1-Year Comparison Of A Stable Dose Of SERETIDE Inhaler With An Adjustable Maintenance Dose Of SYMBICORT Inhaler SERETIDE Inhaler is a Trademark of GSK Group of Companies SYMBICORT Inhaler is a Trademark of Astra Zeneca
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Randomised Double-blind Double-dummy 52-week Parallel Group Study of a Standard Dosing Regimen With SalmeterolFluticasone propionate50250 Twice Daily Diskus Versus a Symptom-driven Variable Dosing Regimen With FormoterolBudesonide Combination 45160 in Adult Asthmatics
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare a stable dose of salmeterolfluticasone propionate with a variable dose of formoterolbudesonide where the dose is adjusted according to a physician-guided self-management plan
Detailed Description:
A randomised double-blind double-dummy 52-week parallel group study of a standard dosing regimen with salmeterolfluticasone propionate combination 50250mcg bid via the DISKUSACCUHALER inhaler versus a symptom-driven variable dosing regimen with formoterolbudesonide combination 6200mcg via a breath-actuated dry powder reservoir inhalerin adults asthmatics
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None